• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《NCCN 肿瘤学临床实践指南:乳腺癌》第 3.2024 版。

Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

机构信息

Robert H . Lurie Comprehensive Cancer Center of Northwestern University.

Yale Cancer Center/Smilow Cancer Hospital.

出版信息

J Natl Compr Canc Netw. 2024 Jul;22(5):331-357. doi: 10.6004/jnccn.2024.0035.

DOI:10.6004/jnccn.2024.0035
PMID:39019058
Abstract

Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget's disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of systemic therapy (preoperative and adjuvant) options for nonmetastatic breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org.

摘要

乳腺癌采用多学科方法治疗,包括外科肿瘤学、放射肿瘤学和内科肿瘤学。NCCN 肿瘤学临床实践指南(NCCN 指南)包括对原位癌、浸润性乳腺癌、派杰病、叶状肿瘤、炎性乳腺癌患者的临床管理建议,以及妊娠期间乳腺癌的管理建议。本期内容主要侧重于非转移性乳腺癌的全身治疗(术前和辅助)选择的总体管理建议。有关 NCCN 乳腺癌指南的完整版本,请访问 NCCN.org。

相似文献

1
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.《NCCN 肿瘤学临床实践指南:乳腺癌》第 3.2024 版。
J Natl Compr Canc Netw. 2024 Jul;22(5):331-357. doi: 10.6004/jnccn.2024.0035.
2
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.《NCCN 肿瘤学临床实践指南:乳腺癌》第 3.2022 版
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. doi: 10.6004/jnccn.2022.0030.
3
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.NCCN 指南®洞察:乳腺癌,第 4.2021 版。
J Natl Compr Canc Netw. 2021 May 1;19(5):484-493. doi: 10.6004/jnccn.2021.0023.
4
Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.乳腺癌筛查与诊断,2018 年第 3 版,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2018 Nov;16(11):1362-1389. doi: 10.6004/jnccn.2018.0083.
5
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.浸润性乳腺癌,2016年第1版,美国国立综合癌症网络(NCCN)肿瘤学临床实践指南
J Natl Compr Canc Netw. 2016 Mar;14(3):324-54. doi: 10.6004/jnccn.2016.0037.
6
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.膀胱癌临床实践指南(第 3 版). 2020 年 NCCN 版
J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011.
7
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.《乳腺癌临床实践指南(NCCN 指南)》第 4 版 2017 年版
J Natl Compr Canc Netw. 2018 Mar;16(3):310-320. doi: 10.6004/jnccn.2018.0012.
8
Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region.中东和北非地区乳腺癌 NCCN 指南的修改和实施。
J Natl Compr Canc Netw. 2010 Jul;8 Suppl 3:S8-S15. doi: 10.6004/jnccn.2010.0126.
9
NCCN Guidelines Insights: Breast Cancer, Version 1.2017.NCCN 指南解读:乳腺癌,第 1.2017 版。
J Natl Compr Canc Netw. 2017 Apr;15(4):433-451. doi: 10.6004/jnccn.2017.0044.
10
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.《癌症相关静脉血栓栓塞疾病》临床实践指南 2024 年版,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2024 Sep;22(7):483-506. doi: 10.6004/jnccn.2024.0046.

引用本文的文献

1
Impact of prior solid tumors and their treatment modality on outcomes after allogeneic hematopoietic stem cell transplantation.既往实体瘤及其治疗方式对异基因造血干细胞移植后结局的影响。
Bone Marrow Transplant. 2025 Sep 15. doi: 10.1038/s41409-025-02718-8.
2
Development and validation of a preoperative nomogram for predicting residual tumor risk in breast cancer patients undergoing excisional biopsy.用于预测接受切除活检的乳腺癌患者残余肿瘤风险的术前列线图的开发与验证
Transl Cancer Res. 2025 Aug 31;14(8):4965-4975. doi: 10.21037/tcr-2025-850. Epub 2025 Aug 27.
3
Prognostic Value of Circulating Tumor DNA in HR+/HER2- Stage I-III Breast Cancer: A Systematic Review.
循环肿瘤DNA在HR+/HER2-Ⅰ-Ⅲ期乳腺癌中的预后价值:一项系统评价
Cancers (Basel). 2025 Aug 29;17(17):2831. doi: 10.3390/cancers17172831.
4
Axillary surgery de-escalation for breast cancer in the era of precision medicine.精准医学时代乳腺癌腋窝手术的降阶梯治疗
Cancer Biol Med. 2025 Sep 4;22(8):871-3. doi: 10.20892/j.issn.2095-3941.2025.0255.
5
Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis.细胞周期蛋白依赖性激酶4/6抑制剂对激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌患者的治疗效果及不良事件:一项系统评价和荟萃分析
Ann Med. 2025 Dec;57(1):2557509. doi: 10.1080/07853890.2025.2557509. Epub 2025 Sep 8.
6
Endocrine Management of Adult Gender-Dysphoric/Gender-Incongruent Persons: A Clinical Practice Guideline from Endocrine Society of India.成年性别焦虑/性别不一致者的内分泌管理:印度内分泌学会临床实践指南。
Indian J Endocrinol Metab. 2025 Jul-Aug;29(4):366-380. doi: 10.4103/ijem.ijem_144_25. Epub 2025 Aug 26.
7
MRI Radiomics Signatures of 21-Gene Recurrence Score for Predicting Survival in ER+/HER2- Breast Cancer.用于预测雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌生存的21基因复发评分的MRI影像组学特征
Cancer Med. 2025 Sep;14(17):e71172. doi: 10.1002/cam4.71172.
8
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy.新辅助化疗后三阴性乳腺癌患者的辅助性卡培他滨治疗
ESMO Open. 2025 Aug 28;10(9):105568. doi: 10.1016/j.esmoop.2025.105568.
9
Feasibility of the omission of axillary surgery in node-negative early breast cancer: a systematic review and meta-analysis.腋窝淋巴结阴性早期乳腺癌省略腋窝手术的可行性:一项系统评价和荟萃分析。
Breast. 2025 Aug 22;83:104559. doi: 10.1016/j.breast.2025.104559.
10
Epitranscriptomic mechanisms and implications of RNA mC modification in cancer.癌症中RNA mC修饰的表观转录组学机制及其影响
Theranostics. 2025 Jul 25;15(16):8404-8428. doi: 10.7150/thno.112332. eCollection 2025.